Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Med Genet

SUPPLEMENT

METHODS

The association between baseline characteristics and the risk of FACE was assessed using a Cox proportional hazards model that treated time to the first FACE (either a composite FACE or each event category) as a dependent variable. The group assignment ERT naïve versus ERT experienced, classic versus others (ERT naïve), multiorgan involvement versus others (ERT experienced), or age ≤40 years versus age >40 years was an independent variable. Furthermore, the following baseline variables were used in each model as covariates: age, time since Fabry diagnosis, previous clinical event, urine protein at baseline, LVMI at baseline and $eGFR_{CKD-EPI}$ at baseline. Prior clinical events were events that occurred before the initiation of migalastat therapy and were identified from patients' medical history using preferred terms in MedDRA version 16.1: microalbuminuria, proteinuria, renal failure, renal failure chronic, renal impairment, nephropathy, myocardial infarction, unstable cardiac angina, congestive heart failure, any major cardiac medical procedure, stroke and transient ischaemic attack. Prior cardiac events also include new symptomatic arrhythmia requiring a medication, direct current cardioversion, pacemaker, or defibrillator implantation, as evaluated by a physician. In addition to covariates, an independent binary variable (ERT naïve versus ERT experienced, classic versus others [ERT naïve], multiorgan involvement versus others [ERT experienced], or age ≤40 years versus age >40 years) was always kept in the model and its significance was tested to see if there was a difference in the time of the first FACE adjusted by covariates. The impact of each covariate on the time to the first FACE was evaluated individually. The impact of each covariate was evaluated in three sets of data (ERT naïve, ERT experienced and all data). Patients who discontinued from the studies or had not experienced any events at data cut-off were right censored.

Search strategy for historical Fabry publications reporting FACE incidence

Relevant publications reporting on FACE incidence, definitions and outcomes in Fabry disease were identified via PubMed using the following search strategy:

- (Agalsidase beta) AND (events)
- (Agalsidase beta) AND (composite)
- (Agalsidase alfa) AND (events)
- (Agalsidase alfa) AND (composite)
- (migalastat) AND (composite)
- (migalastat) AND (events)

Publications including paediatric data and reviews were excluded. Abstracts for publications identified in the search were screened for relevance; full papers were analysed if the abstract met the relevance criteria. Searches were carried out in February 2022.

RESULTS

Supplemental Table 1. Genotypes of patients with classic and multiorgan phenotypes

Classic males *FACETS: <3% enzyme activity; multiorgan involvement at baseline*				Multiorgan males *ATTRACT: multiorgan involvement at baseline*			
Patient number	Age range (years)	Sex	Genotype	Patient number	Age range (years)	Sex	Genotype
1	21–30	M	G183D	15	61–70	M	R363H
2	31–40	M	L243F	16	51–60	M	G35R
3	61–70	M	I253T	17	21–30	M	P205T
4	61–70	M	I253T	18	51–60	M	N215S
5	21–30	M	C174R	19	41–50	M	D322E
6	21–30	M	D55V/Q57L	20	16–20	M	D322E
7	31–40	M	G144V	21	51–60	M	N215S
8	51–60	M	R301Q	22	51–60	M	N215S
9	41–50	M	G373S	23	51–60	M	N215S
10	61–70	M	D322E	24	61–70	M	N215S
11	16–20	M	G325R	25	31–40	M	M284T
12	31–40	M	Y216C	26	41–50	M	R112G
13	41–50	M	P259R	27	51–60	M	L403S
14	41–50	M	P259R	28	41–50	M	M96I
				29	16–20	M	G85D
				30	41–50	M	A156T

M, male.

Enzyme Replacement Therapy (ERT)-naïve patients were stratified by phenotype. Male patients were classified as having the classic phenotype if they had residual white blood cell (WBC) α-Galactosidase A (α-Gal A) activity <3% of normal and multiorgan involvement, which was defined as involvement of ≥2 of the following organ systems: renal, cardiac, central nervous system, peripheral nervous system and gastrointestinal system. A subset of ERT-experienced male patients who had multiorgan involvement at baseline were analysed and were not evaluated by phenotype because their baseline WBC α-Gal A activity may have been confounded by previous ERT.

Supplemental Table 2. Baseline patient demographics and disease characteristics by treatment group

	ERT-treated patients n=15	Migalastat-treated patients n=49
Sex, n (%)		
Male	5 (33.3)	19 (38.8)
Female	10 (66.7)	30 (61.2)
Age, years		
Mean (SD)	45.5 (15.89)	50.0 (13.98)
Median (Q1, Q3)	48.0 (35.0, 57.0)	54.0 (43.0, 59.0)
Time since Fabry diagnosis, years		
Mean (SD)	16.93 (13.56)	12.45 (11.93)
Median (Q1, Q3)	10.0 (6.0, 27.0)	6.0 (5.0, 18.0)
eGFR$_{CKD-EPI}$, mean (SD), mL/min/1.73 m^2	95.81 (21.04)	88.96 (20.39)
eGFR$_{CKD-EPI}$ category, n (%)		
>90 mL/min/1.73 m^2	10 (66.7)	24 (49.0)
60–90 mL/min/1.73 m^2	4 (26.7)	22 (44.9)
>30–<60 mL/min/1.73 m^2	1 (6.7)	3 (6.1)
Urinary protein, median (Q1, Q3), mg/24h	108.0 (0.0, 279.0)	116.0 (0.0, 265.0)
LVMI, mean (SD), g/m^2	88.51 (25.64)	91.48 (26.32)
Patients taking ACEI/ARB/RI, n (%)	8 (53.3)	26 (53.1)

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR$_{CKD-EPI}$, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation; ERT, enzyme replacement therapy; LVMI, left ventricular mass index; RI, renin inhibitor; SD, standard deviation.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Med Genet

Supplemental Table 3. Associations between baseline variables and the risk of FACEs (composite events)

	ERT naïve (N=43)	ERT experienced (N=48)	Total (N=91)
HR (95% CI)*			
eGFR at baseline (per 10 mL/min/1.73m^2)	**0.41 (0.25, 0.66)**	0.65 (0.37, 1.14)	**0.68 (0.55, 0.85)**
Baseline LVMi (per 5 g/m^2)	1.05 (0.99, 1.11)	1.09 (0.94, 1.27)	1.04 (0.98, 1.10)
24-h urine proteinuria at baseline (per 1000 mg/24 h)	0.61 (0.22, 1.73)	1.42 (0.92, 2.19)	1.34 (0.93, 1.95)
Previous events	**3.81 (1.07, 13.56)**	0.48 (0.07, 3.14)	1.15 (0.51, 2.61)
Time from Fabry diagnosis (per 5 years)	1.46 (0.99, 2.17)	0.91 (0.63, 1.32)	1.00 (0.81, 1.24)
Age (per 5 years)	0.72 (0.47, 1.11)	1.20 (0.76, 1.90)	1.05 (0.83, 1.33)

CI, confidence interval; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; FACEs, Fabry-associated clinical events; LVMI, left ventricular mass index.

Composite events is the total of all events that included all cardiac, cerebrovascular and renal events (as previously defined) and death due to FACE. Hazard ratio <1 indicates ERT-naïve patients fared better and hazard ratio >1 indicates ERT-experienced patients fared better. Data set in bold indicates a statistically significant outcome. *Calculated through three separate Cox proportional regression models for ERT naïve, ERT experienced and overall.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Med Genet

Supplemental Table 4. FACE definitions and outcomes across various Fabry studies

Supplemental Figure 1. Study design for the FACET and ATTRACT studies and their open-label extensions

Supplemental Figure 2. Kaplan–Meier analysis of time to first composite event by (A) age, (B) phenotype in ERT-naïve patients and (C) multiorgan involvement in ERT-experienced patients

A.

B.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Med Genet

C.

Comparison groups	*P* value by log rank test
ERT-experienced males with multiorgan involvement vs ERT-experienced others	0.46

ERT, enzyme replacement therapy; FACEs, Fabry-associated clinical events.

Time to first composite event by A) age (≤40 years or >40 years), of which was further analysed according to ERT status (ERT-naïve and ERT-experienced patients), B) phenotype (classic or other) of ERT-naïve patients or C) multiorgan involvement in ERT-experienced patients. ERT-naïve classic males was defined as males with multiorgan involvement (ie at least 2 organs of the renal system, cardiac system, central nervous system, peripheral nervous system and gastrointestinal system are affected) and baseline white blood cell α-Galactosidase A <3% of wild type. ERT-naïve 'other' patients include non-classic males and all females. ERT-naïve is defined as never having received ERT or not having received ERT for >6 months; ERT experienced is defined as having initiated ERT >12 months prior to the study. Composite event included cardiac, cerebrovascular and renal events (as previously defined) and death due to FACE. Number of subjects with events at time 0 is 0.